The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Regulatory News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.65
Bid: 3.60
Ask: 3.70
Change: -0.04 (-1.08%)
Spread: 0.10 (2.778%)
Open: 4.00
High: 4.05
Low: 3.65
Prev. Close: 3.69
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition

4 Jun 2007 07:02

Fabian Romania Property Fund Ltd04 June 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or the "Fund") Fabian Romania announces the purchase of a €4.9 million office building inBucharest Fabian Romania has reached agreement to purchase the Evocenter office buildingin the Pipera / Voluntari district of Bucharest for a forecast yield of 9 percent.. The Evocenter will be the Fund's fourth office building in Bucharest. The fund had initially proposed to purchase the building empty, thereby takingthe letting risk. However, during the due diligence process, the Adama Groupfrom Israel, the developer, signed a lease taking half of the available space.The building will be completed in summer 2007 to a Class A standard andcomprises 3,000m2 of net lettable area, 18 covered car parking spaces andancillary parking close by. It is arranged over seven levels, basement, groundfloor, mezzanine and four office floors. Rents that will be achieved for the building are forecast to be €12 sqm/monthfor ground, mezzanine and floors one to four, €65 sqm/month for parking and €7sqm/month for storage. Once all space is fully let, the yield is forecast to be9 per cent.. The Fund will meet the consideration of €4.9 million from its own resources.Debt drawdown is anticipated to be during the third quarter 2007 which willreduce the ongoing equity requirement to around €1 million. Commenting on the transaction, Mark Holdsworth, Managing Director of FabianCapital, the Investment Advisor to the Fund said: "We are delighted that the Fund has sealed agreement to buy this commercialoffice building. Based on our experience and given the ongoing shortage ofoffice space in Bucharest, we believe it is in the Fund's interest to agree totake the letting risk for the building in return for sealing a more attractiveprice. By having the Adama Group, as both anchor tenant and vendor, we consider we haveensured a quality product through the alignment of interests. We are confidentof letting the rest of the building out to multinational tenants in the nearfuture." Following the acquisition of 40-44 Banu Antonache in January 2006, the purchaseof the Adama building will be the second occasion the fund has taken the lettingrisk. The lead advisers on the transaction were DTZ (property agent), WSP (technicaladvisers) and Tuca Zbarcea Asociatii (legal adviser). For Comments: Fabian Romania:Mark Holdsworth +44 20 7499 9988 Nominated Adviser:Deloitte & Touche LLPJames Lewis +44 20 7936 3000 Broker:Shore Capital Stockbrokers LimitedDru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 202311:05 amRNSSecond Price Monitoring Extn
9th Jan 202311:00 amRNSPrice Monitoring Extension
5th Dec 20227:00 amRNSHalf-year Report
24th Nov 20227:00 amRNSNotice of Results
31st Oct 20221:47 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSBlock admission six monthly return
23rd Sep 202211:44 amRNSResult of AGM
20th Sep 20221:36 pmRNSDirector/PDMR Shareholding
15th Sep 20223:41 pmRNSGrant of options
14th Sep 20222:05 pmRNSSecond Price Monitoring Extn
14th Sep 20222:01 pmRNSPrice Monitoring Extension
6th Sep 20227:00 amRNSGrant of options
1st Sep 20227:00 amRNSNotice of AGM and Director change
23rd Aug 20227:00 amRNSFinal Results
9th Aug 20227:00 amRNSBispecific designs patent application
5th Aug 20224:41 pmRNSSecond Price Monitoring Extn
5th Aug 20224:35 pmRNSPrice Monitoring Extension
28th Jul 20227:00 amRNSAppointment of Chief Executive Officer
6th May 20227:00 amRNSTrading update
1st Apr 20227:00 amRNSBlock admission six monthly return
14th Mar 20227:00 amRNSUpdate on Board changes
28th Feb 20227:00 amRNSDirector changes
22nd Feb 20224:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20224:35 pmRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSDirectorate Change
10th Feb 202212:49 pmRNSStmnt re Share Price Movement
14th Jan 20227:00 amRNSFormation of New Scientific Advisory Panel
11th Jan 20221:26 pmRNSHolding(s) in Company
31st Dec 20217:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSExercise of share options and total voting rights
14th Dec 20217:00 amRNSExercise of share options and total voting rights
6th Dec 20217:00 amRNSHalf-year Report
2nd Dec 20217:00 amRNSUpdate on R&D
17th Nov 202110:00 amRNSNotice of Results
19th Oct 20214:25 pmRNSGrant of options
7th Oct 20214:40 pmRNSSecond Price Monitoring Extn
7th Oct 20214:35 pmRNSPrice Monitoring Extension
7th Oct 20212:06 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202111:06 amRNSSecond Price Monitoring Extn
7th Oct 202111:00 amRNSPrice Monitoring Extension
7th Oct 20217:00 amRNSNew contract win
27th Sep 20217:00 amRNSTotal Voting Rights
24th Sep 202112:00 pmRNSResult of AGM
24th Sep 20217:00 amRNSAGM Statement
1st Sep 20217:00 amRNSNotice of AGM
31st Aug 20215:00 pmRNSTotal Voting Rights
24th Aug 20217:00 amRNSCollaboration with Eurofins Discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.